Cytomegalovirus

Current Opinion in Infectious Diseases

Volumn 18, Issue 3, 2005, Pages 241-245

  Griffiths, Paul D ^a   Walter, Simone ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Congenital; Cytomegalovirus; Diagnosis; Treatment; Vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GANCICLOVIR; GLYCOPROTEIN B; VIRUS DNA;

CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DRUG TOLERABILITY; FETUS MORTALITY; GUINEA PIG; HEARING LOSS; HUMAN; IMMUNOGENICITY; MENTAL DEFICIENCY; NEUTROPENIA; NONHUMAN; REVIEW; TREATMENT OUTCOME;

EID: 20044381685     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000168385.39390.1b     Document Type: Review

References (51)

1. Stagno S. Cytomegalovirus, In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. Philadelphia: W.B. Saunders; 2000. pp. 389-424.
2. Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992; 326:663-667.
3. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century. Washington, DC: National Academy Press; 2000.
4. Hamprecht K, Maschmann J, Vochem M, et al. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001; 357:513-518.
5. Yeager AS, Palumbo PE, Malachowski N, et al. Sequelae of maternally derived cytomegalovirus infections in premature infants. J Pediatr 1983; 102:918-922.
6. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143:16-25.
7. Bradford RD, Cloud G, Lakeman AD, et al. Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J Infect Dis 2005; 191:227-233. Important natural history data linking the pathogenesis of congenital CMV with CMV in allograft recipients and providing the scientific rationale for testing DBSs.
8. Cope AV, Sweny P, Sabin C, et al. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997; 52:200-205.
9. Barbi M, Binda S, Primache V, et al. Cytomegalovirus DMA detection in Guthrie cards: a powerful tool for diagnosing congenital infection. J Clin Virol 2000; 17:159-165.
10. Binda S, Caroppo S, Dido P, et al. Modification of CMV DNA detection from dried blood spots for diagnosing congenital CMV infection. J Clin Virol 2004; 30:276-279. Further report from a research group who have pioneered the use of DBSs.
11. van der Knaap MS, Vermeulen G, Barkhof F, et al. Pattern of white matter abnormalities at MR imaging: use of polymerase chain reaction testing of Guthrie cards to link pattern with congenital cytomegalovirus infection. Radiology 2004; 230:529-536. Matched control groups used to support the conclusion that CMV causes many cases of idiopathic 'leukodystrophy'.
12. Sugiura S, Yoshikawa T, Nishiyama Y, et al. Detection of herpesvirus DNAs in perilymph obtained from patients with sensorineural hearing loss by real-time polymerase chain reaction. Laryngoscope 2004; 114:2235-2238. Two cases (aged 2 and 3 years) where CMV DNA was negative by PCR in blood but PCR positive in perilymph.
13. Pignatelli S, Dal Monte P, Rossini G, Landini MP. Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev Med Virol 2004; 14:383-410. Comprehensive analysis of the genetic variability of distinct CMV genes and the linkage disequilibrium between some of them.
14. de Vries LS, Gunardi H, Barth PG, et al. The spectrum of cranial ultrasound and magnetic resonance imaging abnormalities in congenital cytomegalovirus infection. Neuropediatrics 2004; 35:113-119. Recommends investigation by MRI aided by ultrasound (for intracranial calcifications).
15. Saigal S, Lunyk O, Larke RP, Chernesky MA. The outcome in children with congenital cytomegalovirus infection: a longitudinal follow-up study. Am J Dis Child 1982; 136:896-901.
16. Stagno S, Reynolds DW, Huang ES, et al. Congenital cytomegalovirus infection. N Engl J Med 1977; 296:1254-1258.
17. Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics 1992; 90:862-866.
18. Peckham CS, Stark O, Dudgeon JA, et al. Congenital cytomegalovirus infection: a cause of sensorineural hearing loss. Arch Dis Child 1987; 62:1233-1237.
19. Fowler KB, McCollister FP, Dahle AJ, et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 1997; 130:624-630.
20. Dahle AJ, Fowler KB, Wright JD, et al. Longitudinal investigation of hearing disorders in children with congenital cytomegalovirus. J Am Acad Audio 2000; 11:283-290.
21. Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed? J Pediatr 1999; 135:60-64.
22. Harris S, Ahlfors K, Ivarsson S, et al. Congenital cytomegalovirus infection and sensorineural hearing loss. Eur Hear 1984; 5:352-355.
23. Hicks T, Fowler K, Richardson M, et al. Congenital cytomegalovirus infection and neonatal auditory screening. J Pediatr 1993; 123:779-782.
24. Dahle AJ, McCollister FP, Stagno S, et al. Progressive hearing impairment in children with congenital cytomegalovirus infection. J Speech Hear Disord 1979; 44:220-229.
25. Darmstadt GL, Keithley EM, Harris JP. Effects of cyclophosphamide on the pathogenesis of cytomegalovirus-induced labyrinthitis. Ann Otol Rhinol Laryngol 1990; 99:960-968.
26. Griffiths PD, Stagno S, Pass RF, et al. Congenital cytomegalovirus infection: diagnostic and prognostic significance of the detection of specific immunoglobulin M antibodies in cord serum. Pediatrics 1982; 69:544-549.
27. Keithley EM, Woolf NK, Harris JP. Development of morphological and physiological changes in the cochlea induced by cytomegalovirus. Laryngoscope 1989; 99:409-414.
28. Noyola DE, Demmler GJ, Williamson WD, et al. Cytomegalovirus urinary excretion and long term outcome in children with congenital cytomegalovirus infection. Congenital CMV Longitudinal Study Group. Pediatr Infect Dis J 2000; 19:505-510.
29. Strauss M. Human cytomegalovirus labyrinthitis. Am J Otolaryngol 1990; 11:292-298.
30. Michaels L, Hellquist H. Ear nose and throat histopathology. London: Springer; 2001.
31. Rivera LB, Boppana SB, Fowier KB, et al. Predictors of hearing loss in children with symptomatic congenital cytomegalovirus infection. Pediatrics 2002; 110:762-767.
32. Woolf NK, Ochi JW, Silva EJ, et al. Ganciclovir prophylaxis for cochlear pathophysioiogy during experimental guinea pig cytomegalovirus labyrinthitis. Antimicrob Agents Chemother 1988; 32:865-872.
33. Barbi M, Binda S, Caroppo S, et al. A wider role for congenital cytomegalovirus infection in sensorineural hearing loss. Pediatr Infect Dis J 2003; 22:39-42.
34. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289:1008-1011.
35. Boppana SB, Fowler KB, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999; 104(1 Pt 1):55-60.
36. Lazzarotto T, Gabrielli L, Lanari M, et al. Congenital cytomegalovirus infection: recent advances in the diagnosis of maternal infection. Hum Immunol 2004; 65:410-415. Reports extensive experience showing that IgG avidity assays have greatly improved the specificity of diagnosing primary infection.
37. Collinet P, Subtil D, Houfflin-Debarge V, et al. Routine CMV screening during pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 114:3-11. A review of the pros and cons of considering screening programmes for maternal or congenital CMV.
38. Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 2004; 145:485-491. A randomized trial to provide the evidence-base for recommending specific interventions. Suggests, but does not prove, that pregnant women could be protected in this way.
39. Fowler KB, Stagno S, Pass RF. Interval between births and risk of congenital cytomegalovirus infection. Clin Infect Dis 2004; 38:1035-1037. Important natural history data to support counselling given to women contemplating another pregnancy.
40. Jim WT, Shu CH, Chiu NC, et al. Transmission of cytomegalovirusfrom mothersto preterm infants by breast milk. Pediatr Infect Dis J 2004; 23:848-851.
41. Mussi-Pinhata MM, Yamamoto AY, do Carmo Rego MA, et al. Perinatal or early-postnatal cytomegalovirus infection in preterm infants under 34 weeks gestation born to CMV-seropositive mothers within a high-seroprevalence population. J Pediatr 2004; 145:685-688.
42. Vollmer B, Seibold-Weiger K, Schmitz-Salue C, et al. Postnatally acquired cytomegalovirus infection via breast milk: effects on hearing and development in preterm infants. Pediatr Infect Dis J 2004; 23:322-327.
43. Gibson L, Piccinini G, Lilleri D, et al. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 2004; 172:2256-2264. Important information on the immunological responses to CMV in this age group.
44. Elbou Ould MA, Luton D, Yadini M, et al. Cellular immune response of fetuses to cytomegalovirus. Pediatr Res 2004; 55:280-286. Difficult-to-obtain data which extend knowledge of the fetal immune response.
45. Schleiss MR, Bourne N, Bernstein DI. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 2003; 188:1868-1874.
46. Schleiss MR, Bourne N, Stroup G, et al. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 2004; 189: 1374-1381. Careful clinical studies which show what could be obtained in humans.
47. Frey SE, Harrison C, Pass RF, et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999; 180:1700-1703.
48. Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970-975.
49. Mitchell DK, Holmes SJ, Burke RL, et al. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002; 21:133-138.
50. Arvin AM, Fast P, Myers M, et al. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 2004; 39:233-239. Good update on the current status of CMV vaccines. Concludes that vaccine development should remain a high priority and clinical trials should be accelerated.
51. Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 2001; 19:1356-1362.